Generic Rybix ODT Availability

Rybix ODT is a brand name of tramadol, approved by the FDA in the following formulation(s):

RYBIX ODT (tramadol hydrochloride - tablet, orally disintegrating; oral)

  • Manufacturer: SHIONOGI INC
    Approval date: May 5, 2005
    Strength(s): 50MG [RLD]

Has a generic version of Rybix ODT been approved?

No. There is currently no therapeutically equivalent version of Rybix ODT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rybix ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Rapidly disintegratable multiparticular tablet
    Patent 5,464,632
    Issued: November 7, 1995
    Inventor(s): Cousin; Gerard & Bruna; Etienne & Gendrot; Edouard
    Assignee(s): Laboratoires Prographarm
    Rapidly disintegratable multiparticulate tablet the excipient mixture of which is suitable for imparting a disintegration rate such that the tablet disintegrates in the mouth in an extremely short time, notably in less than sixty seconds, characterized by the fact that the active substance is present in the form of coated microcrystals or coated or uncoated microgranules.
    Patent expiration dates:
    • March 22, 2013
      ✓ 
      Drug product
  • Multiparticulate tablet disintegrating in less than 40 seconds in the mouth
    Patent 6,106,861
    Issued: August 22, 2000
    Inventor(s): Chauveau; Charles & Gendrot; Edouard & Demichelis; Alain Gilles & Nouri; Noureddine
    Assignee(s): Laboratoires Prographarm
    The invention relates to a rapidly disintegratable multiparticulate tablet which disintegrates in the mouth in less than 40 seconds and which comprises an excipient and an active ingredient in the form of microcrystals coated with a coating agent. The excipient comprises, with respect to the mass of the tablet, from 3 to 15% by weight of at least one disintegration agent and from 40 to 90% by weight of at least one soluble diluent agent with binding properties consisting of a polyol having less than 13 carbon atoms, said polyol being either in the directly compressible form which is composed of particles whose average diameter is from 100 to 500 micrometers or in the powder form which is composed of particles whose average diameter is less than 100 micrometers, said polyol being selected from the group consisting of mannitol, xylitol, sorbitol and maltitol, with the proviso that, when only one soluble diluent agent with binding properties is used, it is a polyol in the directly compressible form except sorbitol and, when at least two soluble diluent agents with binding properties are used, one is consisting of a polyol in the directly compressible form and the other is consisting of the same or another polyol in powder form, the proportion of directly compressible polyol to powder polyol being from 99/1 to 50/50.
    Patent expiration dates:
    • December 5, 2017
      ✓ 
      Drug product

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Suffering from knee pain? Find out how real people manage OA of the Knee. Watch Video

Close
(web2)